Incyte Corporation (NASDAQ: INCY) reported results from its Phase 3 frontMIND trial showing that tafasitamab combined with lenalidomide plus R-CHOP ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE